Add-on Acquisition • Life Science

Onconetix Acquires Proteomedix

On December 18, 2023, Onconetix acquired life science company Proteomedix

Acquisition Context

This is Onconetix’s 1st transaction in the Life Science sector.
This is Onconetix’s 1st transaction in Switzerland.

Explore All 3111 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	December 18, 2023
Target	Proteomedix
Sector	Life Science
Buyer(s)	Onconetix
Deal Type	Add-on Acquisition
Advisor(s)	Tungsten Advisors (Financial)

Target Company

Proteomedix

Schlieren, Switzerland

Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis, and therapy management. Its product Proclarix is a blood-based prostate cancer test panel and risk score currently available in Europe and expected to be available in the U.S. Proteomedix is based in Schlieren, Switzerland.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Onconetix

Cincinnati, Ohio, United States

Category	Company
Founded	2018
Sector	Life Science
Employees	5
Revenue	3M USD (2024)

DESCRIPTION

Onconetix is a commercial stage biotechnology company focused on the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for clinicians and patients for oncology. The Company currently has Entadfi, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Onconetix was founded in 2018 and is based in Cincinnati, Ohio.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: Switzerland	1 of 1
Year: 2023	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Switzerland M&A - 2023 M&A